Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Expands By 38.8%

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 42,600 shares, an increase of 38.8% from the August 15th total of 30,700 shares. Based on an average trading volume of 136,900 shares, the short-interest ratio is currently 0.3 days.

Astellas Pharma Price Performance

Shares of ALPMY stock opened at $12.01 on Friday. Astellas Pharma has a 1 year low of $9.15 and a 1 year high of $15.44. The company has a current ratio of 0.90, a quick ratio of 0.72 and a debt-to-equity ratio of 0.26. The firm’s 50 day moving average is $11.50 and its 200-day moving average is $10.59. The firm has a market capitalization of $21.73 billion, a price-to-earnings ratio of 171.57 and a beta of 0.38.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.24 earnings per share (EPS) for the quarter. The firm had revenue of $3.03 billion for the quarter. Astellas Pharma had a return on equity of 7.79% and a net margin of 1.17%. Sell-side analysts forecast that Astellas Pharma will post 0.54 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.